Biogen (BIIB) PT Raised to $274 at Wedbush, Following CFO Transition, Earnings
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $209.68 -0.07%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
Wedbush analyst Laura Chico raised the price target on Biogen (NASDAQ: BIIB) to $274.00 (from $262.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- JD Logistics Inc (2618:HK) (JDLGF) PT Raised to HK$18.50 at Macquarie
- Maxis Bhd (MAXIS:MK) (MAXSF) PT Raised to MYR3.82 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
